Enantioselective immunoaffinity extraction for simultaneous determination of optically active bufuralol and its metabolites in human plasma by HPLC

被引:16
作者
Ikegawa, S
Matsuura, K
Sato, T
Isriyanthi, NMR
Niwa, T
Miyairi, S
Takashina, H
Kawashima, Y
Goto, J
机构
[1] Tohoku Univ, Fac Pharmaceut Sci, Sendai, Miyagi 98077, Japan
[2] Santen Pharmaceut Co Ltd, Higashiyodogawa Ku, Osaka 533, Japan
关键词
bufuralol; immobilized antibody; chiral separation; immunoaffinity extraction; high-performance liquid chromatography;
D O I
10.1016/S0731-7085(97)00147-7
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A combined method of immunoaffinity extraction with high-performance liquid chromatography has been developed for the enantioselective determination of bufuralol and its metabolites in human plasma. The antibodies having high affinity toward the asymmetric center at the C-1 position of bufuralol and its 1'-oxidized metabolites and low affinity to their antipodes were elicited by immunization of rabbits with immunogens, (1R)- and (1S)-1'-oxobufuralol O-carboxymethyloxime-bovine serum albumin conjugates, respectively. 0.5 ml Of the immunoaffinity adsorbent (7.6 mg.ml(-1) for anti-(1S)-antibody and 28.8 mg.ml(-1) for anti-(1R)-antibody) prepared by immobilization of an antibody was capable of retaining up to 1 mu g of (R)- and (S)-bufuralol and up to 500 ng of other metabolites. The adsorbates were recovered quantitatively by elution with methanol-10 mM ammonium acetate buffer (pH 5) (95:5, v/v) without any interfering peaks on the high-performance liquid chromatogram. The proposed method was evaluated to be useful for the simultaneous determination of optically active bufuralol and its metabolite in plasma with acceptable recovery and precision. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 19 条
[1]   STEREOCHEMISTRY, A BASIS FOR SOPHISTICATED NONSENSE IN PHARMACOKINETICS AND CLINICAL-PHARMACOLOGY [J].
ARIENS, EJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 26 (06) :663-668
[2]  
AWATA N, 1994, BIOL PHARM BULL, V17, P843
[3]  
BLABER LC, 1984, J CARDIOVASC PHARM, V6, P165
[4]   THE GENETIC-CONTROL OF BUFURALOL METABOLISM IN MAN [J].
DAYER, P ;
BALANT, L ;
COURVOISIER, F ;
KUPFER, A ;
KUBLI, A ;
GORGIA, A ;
FABRE, J .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1982, 7 (01) :73-77
[5]  
FOTHERGILL GA, 1977, ARZNEIMITTEL-FORSCH, V27, P978
[6]   KINETICS AND METABOLISM OF (+)-BUFURALOL, (-)-BUFURALOL AND (+/-)-BUFURALOL [J].
FRANCIS, RJ ;
EAST, PB ;
LARMAN, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 23 (06) :529-533
[7]  
FRANCIS RJ, 1976, EUR J DRUG METAB PH, V1, P113
[8]  
GLASKELL SJ, 1983, CLIN CHEM, V29, P677
[9]   THE USE OF OESTRADIOL-17-BETA ANTISERUM COVALENTLY COUPLED TO SEPHAROSE TO EXTRACT OESTRADIOL-17-BETA FROM BIOLOGICAL-FLUIDS [J].
GLENCROSS, RG ;
ABEYWARDENE, SA ;
CORNEY, SJ ;
MORRIS, HS .
JOURNAL OF CHROMATOGRAPHY, 1981, 223 (01) :193-197
[10]   INTRINSIC SYMPATHOMIMETIC ACTIVITY OF BETA-ADRENOCEPTOR BLOCKING-DRUGS AT CARDIAC AND VASCULAR BETA-ADRENOCEPTORS [J].
HAMILTON, TC ;
CHAPMAN, V .
LIFE SCIENCES, 1978, 23 (08) :813-819